{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T13:02:51Z","timestamp":1789736571624,"version":"4.0.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,8]],"date-time":"2020-07-08T00:00:00Z","timestamp":1594166400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,8]],"date-time":"2020-07-08T00:00:00Z","timestamp":1594166400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pancreatic cancer has a poor prognosis and few choices of therapy. For patients with adequate performance status, FOLFIRINOX or gemcitabine plus nab-paclitaxel are preferred first-line treatment. 5-Fluorouracil (5-FU)\u2013based therapy (e.g. FOLFIRI, OFF, or FOLFOX) are often used in patients who previously received gemcitabine-based regimens. A systematic review was conducted of the safety and efficacy of FOLFOX for metastatic pancreatic cancer following prior gemcitabine-based therapy. A Bayesian fixed-effect meta-analysis with adjustment of patient performance status (PS) was conducted to evaluate overall survival (OS) and compare outcomes with nanoliposomal irinotecan combination therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/pubmed.gov\">PubMed.gov<\/jats:ext-link>\n                      ,\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/fda.gov\">FDA.gov<\/jats:ext-link>\n                      ,\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link>\n                      , congress abstracts,\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/cochrane.org\">Cochrane.org<\/jats:ext-link>\n                      library, and EMBASE database searches were conducted to identify randomized controlled trials of advanced\/metastatic disease, prior gemcitabine-based therapy, and second-line treatment with 5-FU and oxaliplatin. The database search dates were January 1, 1990\u2013June 30, 2019. Endpoints were OS and severe treatment-related adverse events (TRAEs). Trial-level PS scores were standardized by converting Karnofsky grade scores to Eastern Cooperative Oncology Group (ECOG) Grade, and overall study-weighted PS was calculated based on weighted average of all patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 282 studies identified, 11 randomized controlled trials (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u2009454) were included in the meta-analysis. Baseline weighted PS scores predicted OS in 10 of the 11 studies, and calculated PS scores of 1.0 were associated with a median OS of 6.3\u2009months (95% posterior interval, 5.4\u20137.4). After adjusting for baseline PS, FOLFOX had a similar treatment effect profile (median OS, range 2.6\u20136.7\u2009months) as 5-FU\/leucovorin plus nanoliposomal irinotecan therapy (median OS, 6.1\u2009months; 95% confidence interval 4.8\u20138.9). Neutropenia and fatigue were the most commonly reported Grade 3\u20134 TRAEs associated with FOLFOX.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Baseline PS is a strong prognostic factor when interpreting the efficacy of 5-FU and oxaliplatin-based therapy of pancreatic cancer after progression on first-line gemcitabine-based regimens. When baseline PS is considered, FOLFOX has a similar treatment effect as 5-FU and nanoliposomal irinotecan therapy and a comparable safety profile. These findings suggest that 5-FU and oxaliplatin-based therapies remain an acceptable and alternative second-line treatment option for patients with pancreatic cancer and adequate PS (e.g. ECOG 0\u20131) following gemcitabine treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-020-07110-x","type":"journal-article","created":{"date-parts":[[2020,7,8]],"date-time":"2020-07-08T09:03:51Z","timestamp":1594199031000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy: effect of performance status and comparison with other regimens"],"prefix":"10.1186","volume":"20","author":[{"given":"Zev A.","family":"Wainberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kynan","family":"Feeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myung Ah","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Cubillo","family":"Graci\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Lonardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baek-Yeol","family":"Ryoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Bendell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Randolph","family":"Hecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,8]]},"reference":[{"issue":"6","key":"7110_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424.","journal-title":"CA Cancer J Clin"},{"key":"7110_CR2","volume-title":"Common cancer types","author":"National Cancer Institute","year":"2019","unstructured":"National Cancer Institute. Common cancer types 2019. Available from: https:\/\/www.cancer.gov\/types\/common-cancers."},{"issue":"1","key":"7110_CR3","doi-asserted-by":"publisher","first-page":"10","DOI":"10.14740\/wjon1166","volume":"10","author":"P Rawla","year":"2019","unstructured":"Rawla P, Sunkara T, Gaduputi V. Epidemiology of pancreatic cancer: global trends, etiology and risk factors. World J Oncol. 2019;10(1):10\u201327.","journal-title":"World J Oncol"},{"issue":"19","key":"7110_CR4","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, Bouch\u00e9 O, Guimbaud R, B\u00e9couarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817\u201325.","journal-title":"N Engl J Med"},{"issue":"18","key":"7110_CR5","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691\u2013703.","journal-title":"N Engl J Med"},{"key":"7110_CR6","volume-title":"National Comprehensive Cancer Network (NCCN) pancreatic adenocarcinoma (v3.2019)","author":"National Comprehensive Cancer Network","year":"2019","unstructured":"National Comprehensive Cancer Network. National Comprehensive Cancer Network (NCCN) pancreatic adenocarcinoma (v3.2019) 2019. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/pancreatic.pdf."},{"issue":"4","key":"7110_CR7","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1177\/1756283X13478680","volume":"6","author":"PE Oberstein","year":"2013","unstructured":"Oberstein PE, Olive KP. Pancreatic cancer: why is it so hard to treat? Ther Adv Gastroenterol. 2013;6(4):321\u201337.","journal-title":"Ther Adv Gastroenterol"},{"issue":"4","key":"7110_CR8","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1002\/ags3.12176","volume":"2","author":"RJ Torphy","year":"2018","unstructured":"Torphy RJ, Zhu Y, Schulick RD. Immunotherapy for pancreatic cancer: barriers and breakthroughs. Ann Gastroenterol Surg. 2018;2(4):274\u201381.","journal-title":"Ann Gastroenterol Surg"},{"issue":"12","key":"7110_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0208557","volume":"13","author":"T Mori","year":"2018","unstructured":"Mori T, Hamaya Y, Uotani T, Yamade M, Iwaizumi M, Furuta T, et al. Prevalence of elevated microsatellite alterations at selected tetranucleotide repeats in pancreatic ductal adenocarcinoma. PLoS One. 2018;13(12):e0208557.","journal-title":"PLoS One"},{"issue":"6","key":"7110_CR10","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1158\/1078-0432.CCR-17-3099","volume":"24","author":"ZI Hu","year":"2018","unstructured":"Hu ZI, Shia J, Stadler ZK, Varghese AM, Capanu M, Salo-Mullen E, et al. Evaluating mismatch repair deficiency in pancreatic adenocarcinoma: challenges and recommendations. Clin Cancer Res. 2018;24(6):1326\u201336.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"7110_CR11","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1903387","volume":"381","author":"T Golan","year":"2019","unstructured":"Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019;381(4):317\u201327.","journal-title":"N Engl J Med"},{"issue":"10018","key":"7110_CR12","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S0140-6736(15)00986-1","volume":"387","author":"A Wang-Gillam","year":"2016","unstructured":"Wang-Gillam A, Li CP, Bodoky G, Dean A, Shan YS, Jameson G, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet. 2016;387(10018):545\u201357.","journal-title":"Lancet"},{"key":"7110_CR13","volume-title":"eUpdate \u2013 Cancer of the pancreas treatment recommendations","author":"ESMO","year":"2017","unstructured":"ESMO. eUpdate \u2013 Cancer of the pancreas treatment recommendations 2017. Available from: https:\/\/www.esmo.org\/Guidelines\/Gastrointestinal-Cancers\/Cancer-of-the-Pancreas\/eUpdate-Treatment-Recommendations."},{"issue":"23","key":"7110_CR14","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1200\/JCO.2013.53.6995","volume":"32","author":"H Oettle","year":"2014","unstructured":"Oettle H, Riess H, Stieler JM, Heil G, Schwaner I, Seraphin J, et al. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. J Clin Oncol. 2014;32(23):2423\u20139.","journal-title":"J Clin Oncol"},{"issue":"4","key":"7110_CR15","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1001\/jamaoncol.2016.5383","volume":"3","author":"V Chung","year":"2017","unstructured":"Chung V, McDonough S, Philip PA, Cardin D, Wang-Gillam A, Hui L, et al. Effect of selumetinib and MK-2206 vs oxaliplatin and fluorouracil in patients with metastatic pancreatic cancer after prior therapy: SWOG S1115 study randomized clinical trial. JAMA Oncol. 2017;3(4):516\u201322.","journal-title":"JAMA Oncol"},{"issue":"32","key":"7110_CR16","doi-asserted-by":"publisher","first-page":"3914","DOI":"10.1200\/JCO.2016.68.5776","volume":"34","author":"S Gill","year":"2016","unstructured":"Gill S, Ko YJ, Cripps C, Beaudoin A, Dhesy-Thind S, Zulfiqar M, et al. PANCREOX: a randomized phase III study of fluorouracil\/leucovorin with or without oxaliplatin for second-line advanced pancreatic cancer in patients who have received gemcitabine-based chemotherapy. J Clin Oncol. 2016;34(32):3914\u201320.","journal-title":"J Clin Oncol"},{"issue":"11","key":"7110_CR17","first-page":"5121","volume":"32","author":"K Furukawa","year":"2012","unstructured":"Furukawa K, Uwagawa T, Iwase R, Haruki K, Fujiwara Y, Gocho T, et al. Prognostic factors of unresectable pancreatic cancer treated with nafamostat mesilate combined with gemcitabine chemotherapy. Anticancer Res. 2012;32(11):5121\u20136.","journal-title":"Anticancer Res"},{"issue":"3","key":"7110_CR18","doi-asserted-by":"publisher","first-page":"423","DOI":"10.3892\/etm.2011.412","volume":"3","author":"DX Zhang","year":"2012","unstructured":"Zhang DX, Dai YD, Yuan SX, Tao L. Prognostic factors in patients with pancreatic cancer. Exp Ther Med. 2012;3(3):423\u201332.","journal-title":"Exp Ther Med"},{"issue":"5","key":"7110_CR19","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s10147-012-0474-9","volume":"18","author":"F Tas","year":"2013","unstructured":"Tas F, Sen F, Odabas H, K\u0131l\u0131c L, Keskin S, Y\u0131ld\u0131z I. Performance status of patients is the major prognostic factor at all stages of pancreatic cancer. Int J Clin Oncol. 2013;18(5):839\u201346.","journal-title":"Int J Clin Oncol"},{"issue":"31","key":"7110_CR20","doi-asserted-by":"publisher","first-page":"10802","DOI":"10.3748\/wjg.v20.i31.10802","volume":"20","author":"A Bilici","year":"2014","unstructured":"Bilici A. Prognostic factors related with survival in patients with pancreatic adenocarcinoma. World J Gastroenterol. 2014;20(31):10802\u201312.","journal-title":"World J Gastroenterol"},{"issue":"5","key":"7110_CR21","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.21037\/tcr.2018.08.34","volume":"7","author":"A Bittoni","year":"2018","unstructured":"Bittoni A, Pellei C, Lanese A, Giampieri R, D\u2019Angelo A, Giglio E, et al. Prognostic factors in advanced pancreatic cancer patients receiving second-line chemotherapy: a single institution experience. Transl Cancer Res. 2018;7(5):1190\u20138.","journal-title":"Transl Cancer Res"},{"issue":"5","key":"7110_CR22","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1245\/s10434-018-07148-z","volume":"26","author":"BA Boone","year":"2019","unstructured":"Boone BA, Zenati MS, Rieser C, Hamad A, Al-Abbas A, Zureikat AH, et al. Risk of venous thromboembolism for patients with pancreatic ductal adenocarcinoma undergoing preoperative chemotherapy followed by surgical resection. Ann Surg Oncol. 2019;26(5):1503\u201311.","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"7110_CR23","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1177\/1724600819881147","volume":"34","author":"ZJ Qi","year":"2019","unstructured":"Qi ZJ, Yu D, Chen CH, Jiang H, Li R, Kang YM. The prognostic value of B7H1 and B7H4 expression in pancreatic cancer: a meta-analysis. Int J Biol Markers. 2019;34(4):373\u201380.","journal-title":"Int J Biol Markers"},{"key":"7110_CR24","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1186\/1471-2407-14-441","volume":"14","author":"A Zaanan","year":"2014","unstructured":"Zaanan A, Trouilloud I, Markoutsaki T, Gauthier M, Dupont-Gossart AC, Lecomte T, et al. FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study. BMC Cancer. 2014;14:441.","journal-title":"BMC Cancer"},{"key":"7110_CR25","volume-title":"Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0","author":"U.S. Department of Health and Human Services","year":"2009","unstructured":"U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 2009. Available from: https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/Archive\/CTCAE_4.0_2009-05-29_QuickReference_8.5x11.pdf."},{"issue":"6","key":"7110_CR26","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol. 1982;5(6):649\u201355.","journal-title":"Am J Clin Oncol"},{"issue":"11","key":"7110_CR27","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1016\/j.ejca.2011.04.011","volume":"47","author":"U Pelzer","year":"2011","unstructured":"Pelzer U, Schwaner I, Stieler J, Adler M, Seraphin J, D\u00f6rken B, et al. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer. 2011;47(11):1676\u201381.","journal-title":"Eur J Cancer"},{"issue":"3","key":"7110_CR28","first-page":"99","volume":"32","author":"U Pelzer","year":"2009","unstructured":"Pelzer U, Stieler J, Roll L, Hilbig A, D\u00f6rken B, Riess H, et al. Second-line therapy in refractory pancreatic cancer. Results of a phase II study. Onkologie. 2009;32(3):99\u2013102.","journal-title":"Onkologie"},{"issue":"4","key":"7110_CR29","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s10637-005-1446-y","volume":"23","author":"N Tsavaris","year":"2005","unstructured":"Tsavaris N, Kosmas C, Skopelitis H, Gouveris P, Kopterides P, Loukeris D, et al. Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: a phase II study. Investig New Drugs. 2005;23(4):369\u201375.","journal-title":"Investig New Drugs"},{"issue":"Suppl 6","key":"7110_CR30","doi-asserted-by":"publisher","first-page":"vi124","DOI":"10.1093\/annonc\/mdm240","volume":"18","author":"V Gebbia","year":"2007","unstructured":"Gebbia V, Maiello E, Giuliani F, Borsellino N, Caruso M, Di Maggio G, et al. Second-line chemotherapy in advanced pancreatic carcinoma: a multicenter survey of the Gruppo Oncologico Italia Meridionale on the activity and safety of the FOLFOX4 regimen in clinical practice. Ann Oncol. 2007;18(Suppl 6):vi124\u20137.","journal-title":"Ann Oncol"},{"issue":"10","key":"7110_CR31","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1038\/sj.bjc.6605374","volume":"101","author":"C Yoo","year":"2009","unstructured":"Yoo C, Hwang JY, Kim JE, Kim TW, Lee JS, Park DH, et al. A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer. Br J Cancer. 2009;101(10):1658\u201363.","journal-title":"Br J Cancer"},{"issue":"120","key":"7110_CR32","first-page":"2635","volume":"59","author":"V Berk","year":"2012","unstructured":"Berk V, Ozdemir N, Ozkan M, Aksoy S, Turan N, Inal A, et al. XELOX vs. FOLFOX4 as second line chemotherapy in advanced pancreatic cancer. Hepatogastroenterology. 2012;59(120):2635\u20139.","journal-title":"Hepatogastroenterology"},{"issue":"3","key":"7110_CR33","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s12029-013-9495-5","volume":"44","author":"HA El-Hadaad","year":"2013","unstructured":"El-Hadaad HA, Wahba HA. Oxaliplatin plus 5-fluorouracil and folinic acid (OFF) in gemcitabine-pretreated advanced pancreatic cancer: a phase II study. J Gastrointest Cancer. 2013;44(3):313\u20137.","journal-title":"J Gastrointest Cancer"},{"issue":"18","key":"7110_CR34","doi-asserted-by":"publisher","first-page":"3116","DOI":"10.1016\/j.ejca.2014.09.015","volume":"50","author":"I Trouilloud","year":"2014","unstructured":"Trouilloud I, Dupont-Gossard AC, Malka D, Artru P, Gauthier M, Lecomte T, et al. Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastatic pancreatic adenocarcinoma: an AGEO randomised phase II study (FIRGEM). Eur J Cancer. 2014;50(18):3116\u201324.","journal-title":"Eur J Cancer"},{"issue":"24","key":"7110_CR35","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1200\/JCO.2018.78.9636","volume":"36","author":"DPS Sohal","year":"2018","unstructured":"Sohal DPS, Kennedy EB, Khorana A, Copur MS, Crane CH, Garrido-Laguna I, et al. Metastatic pancreatic Cancer: ASCO clinical practice guideline update. J Clin Oncol. 2018;36(24):2545\u201356.","journal-title":"J Clin Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07110-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-020-07110-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07110-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T19:26:51Z","timestamp":1625686011000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-020-07110-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,8]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["7110"],"URL":"https:\/\/doi.org\/10.1186\/s12885-020-07110-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-15906\/v1","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,8]]},"assertion":[{"value":"20 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"ZAW has received research funding from AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Company, Ipsen, and Merck, and has served as a consultant and on advisory panels for Bayer, Eli Lilly and Company, Daiichi Sankyo, EMD Serono, Five Prime, Ipsen, Macrogenics, Merck, Molecular Templates, and Novartis. AM has received research funding from Leo Pharma and Sanofi; has served as a consultant and on advisory panels for Bristol-Myers Squibb, Celgene, Daiichi Sankyo, Halozyme, Leo Pharma, Pfizer, and Sanofi; has participated in speaker bureaus for Bayer, Eli Lilly and Company, MSD, Rovi, and Servier; has received reimbursements for travel, accommodations, and expenses from Celgene and Roche; and holds patents, royalties, and other intellectual property (risk assessment model in venous thromboembolism in patients with cancer). SL has received research funding from Amgen and Merck Serono; has served as a consultant and on advisory panels for Amgen, Eli Lilly and Company, Merck Serono, and Servier; and has participated in speaker bureaus for Bristol-Myers Squibb, Eli Lilly and Company, Merck Serono, Roche, and Servier. JB\u2019s institution has received research funding from AbbVie, Acerta Pharma, ADC, Agios, Amgen, Apexigen, Arch Oncology, Arcus Biosciences, ARMO, Array, Arrys, AstraZeneca, Bayer, Bellicum, Blueprint, Boehringer Ingelheim, Boston Biomedical, Bristol-Myers Squibb, Calithera, Celgene, Celldex, CytomX, Daiichi Sankyo, Effector, Eisai, Eli Lilly and Company, EMD Serono, Evelo, Five Prime, FORMA, Forty Seven, Genentech\/Roche, Gilead, Gossamer Bio, GSK, Harpoon, ImClone, Incyte, Innate, Ipsen, Jacobio, Koltan, LEAP, Macrogenics, Marshall Edwards, MedImmune, Merck, Merrimack, Mersana, Merus, Millennium, Nektar, Novartis, Novocare, OncoGenex, OncoMed, Onyx, Pfizer, Pieris, Prelude Oncology, Rgenix, Sanofi, Seattle Genetics, Shattuck Labs, Sierra, SynDevRx, Takeda, Tarveda, Tracon, Tyrogenex, Taiho, TempestTx, TG Therapeutics, Unum Therapeutics, and Vyriad; has served as a consultant and on advisory panels for Agios, Amgen, Apexigen, Arch Oncology, ARMO, Array, AstraZeneca, Bayer, BeiGene, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Continuum Clinical, Cyteir, Daiichi Sankyo, Eli Lilly and Company, Five Prime, FORMA, Genentech\/Roche, Gilead, GSK, Incyte, Innate, Ipsen, Janssen, LEAP, MacroGenics, MedImmune, Merck, Merrimack, Moderna Therapeutics, Molecular Partners, Novartis, OncoGenex, OncoMed, Phoenix Bio, Prelude Therapeutics, Sanofi, Seattle Genetics, Taiho, Tanabe Research Laboratories, TD2 (Translational Drug Development), TG Therapeutics, Tizona, Tolero, and Torque; and has received reimbursements for food, beverage, and travel from ARMO, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly and Company, FORMA, Genentech\/Roche, Gilead, Ipsen, MedImmune, Merck, Novartis, OncoMed, OncoGenex, and Taiho. JRH received grants, personal fees, and non-financial support from ARMO BioSciences, a wholly owned subsidiary of Eli Lilly and Company, during the conduct of the study.AH and YL are employees of Eli Lilly and Company, and YL acknowledges stock\/equity ownership in Eli Lilly and Company. KF, M-AL, ACG, and B-YR have no competing interests to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"633"}}